PortfoliosLab logoPortfoliosLab logo
ISIN
US34960Q2084
CUSIP
34960Q208
IPO Date
Nov 14, 2017

Highlights

Market Cap
$5.80B
Enterprise Value
$5.79B
EPS (TTM)
-$0.28
Total Revenue (TTM)
$63.25M
Gross Profit (TTM)
$31.70M
EBITDA (TTM)
-$21.61M
Year Range
$6.27 - $21.00
ROA (TTM)
-17.05%
ROE (TTM)
-63.42%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Fortress Biotech, Inc.

Performance

FBIOP Performance Chart

Fortress Biotech, Inc. (FBIOP) is up 118.9% since the beginning of the year. At $21 per share, FBIOP is trading just below its 52-week high of $21. Investors who bought $1,000 worth of FBIOP shares 5 years ago would now be looking at an investment worth $1,189.


Loading charts...

S&P 500 Index

Returns By Period

Fortress Biotech, Inc. (FBIOP) has returned 118.86% so far this year and 158.66% over the past 12 months.


Fortress Biotech, Inc.

1D
1.66%
1M
47.51%
YTD
118.86%
6M
198.85%
1Y
158.66%
3Y*
15.50%
5Y*
3.53%
10Y*

Benchmark (S&P 500 Index)

1D
-0.74%
1M
4.90%
YTD
10.35%
6M
10.28%
1Y
26.52%
3Y*
20.83%
5Y*
12.30%
10Y*
13.66%
*Multi-year figures are annualized to reflect compound growth (CAGR)

FBIOP Monthly Returns History

Based on dividend-adjusted daily data since Nov 14, 2017, FBIOP's average daily return is +0.09%, while the average monthly return is +1.44%. At this rate, an investment would double in approximately 4.0 years.

Historically, 61% of months were positive and 39% were negative. The best month was Dec 2025 with a return of +37.5%, while the worst month was Jul 2024 at -46.5%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 5 months.

On a daily basis, FBIOP closed higher 50% of trading days. The best single day was Aug 21, 2023 with a return of +37.2%, while the worst single day was Jul 8, 2024 at -54.8%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202628.56%18.03%-3.40%3.45%35.30%6.68%118.86%
2025-3.31%-9.49%3.26%11.48%17.91%-2.53%-10.78%19.17%12.37%-23.91%-1.43%37.54%42.71%
202414.10%16.47%9.52%-10.01%8.75%1.35%-46.54%-22.60%-17.16%1.83%6.40%12.62%-39.63%
202312.99%-0.36%-4.58%1.19%-11.95%10.25%-1.65%-34.61%8.44%-17.75%27.77%1.00%-21.89%
20220.63%-4.27%-1.50%-6.23%-13.98%-2.91%5.75%6.48%-5.90%3.91%3.01%-9.55%-23.78%
20218.31%7.42%8.39%7.14%2.75%1.34%1.80%-2.68%3.17%0.86%-0.80%2.02%46.78%

Benchmark Metrics

Fortress Biotech, Inc. has an annualized alpha of 17.95%, beta of 0.41, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since November 15, 2017.

  • This stock participated in 46.65% of S&P 500 Index downside but only 43.29% of its upside - more exposed to losses than it benefited from rallies.
  • Beta of 0.41 may look defensive, but with R2 of 0.02 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
17.95%
Beta
0.41
0.02
Upside Capture
43.29%
Downside Capture
46.65%

Return for Risk

Risk / Return Rank

FBIOP ranks 91 for risk / return — in the top 91% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.


FBIOP Risk / Return Rank: 9191
Overall Rank
FBIOP Sharpe Ratio Rank: 9292
Sharpe Ratio Rank
FBIOP Sortino Ratio Rank: 9292
Sortino Ratio Rank
FBIOP Omega Ratio Rank: 9393
Omega Ratio Rank
FBIOP Calmar Ratio Rank: 9292
Calmar Ratio Rank
FBIOP Martin Ratio Rank: 8888
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Fortress Biotech, Inc. (FBIOP) and compare them to S&P 500 Index.


FBIOPBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

+0.27

Sortino ratioReturn per unit of downside risk

+0.47

Omega ratioGain probability vs. loss probability

1.49

1.41

+0.09

Calmar ratioReturn relative to maximum drawdown

5.14

2.93

+2.21

Martin ratioReturn relative to average drawdown

10.34

13.52

-3.18

Dividends

Dividend History

Fortress Biotech, Inc. provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.


0.00%5.00%10.00%15.00%20.00%$0.00$0.50$1.00$1.50$2.00201720182019202020212022202320242025
Dividends
Dividend Yield
PeriodTTM202520242023202220212020201920182017
Dividend$0.00$0.00$1.17$2.34$2.34$2.34$2.34$2.34$2.34$0.30

Dividend yield

0.00%0.00%17.62%19.75%13.28%9.06%12.09%11.44%16.29%1.32%

Monthly Dividends

The table displays the monthly dividend distributions for Fortress Biotech, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2025$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2024$0.20$0.20$0.20$0.20$0.20$0.20$0.00$0.00$0.00$0.00$0.00$0.00$1.17
2023$0.20$0.20$0.20$0.20$0.20$0.20$0.20$0.20$0.20$0.20$0.20$0.20$2.34
2022$0.20$0.20$0.20$0.20$0.20$0.20$0.20$0.20$0.20$0.20$0.20$0.20$2.34
2021$0.20$0.20$0.20$0.20$0.20$0.20$0.20$0.20$0.20$0.20$0.20$0.20$2.34

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Fortress Biotech, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Fortress Biotech, Inc. was 73.54%, occurring on Oct 15, 2024. Recovery took 403 trading sessions.


Related event

Drawdown

Fall

Recovery

Underwater

2024 bear market2024
-73.54%Oct 2024
2y 8mo1y 7mo
4y 4moJan 2022 - May 2026
COVID crash2020
-39.42%Mar 2020
1mo 11d8mo 6d
9mo 17dFeb 2020 - Nov 2020
Rate-hike selloffLate 2018
-35.99%Dec 2018
1y 1mo5mo 4d
1y 6moNov 2017 - May 2019
2021 pullback2021
-9.47%Mar 2021
17d12d
29dFeb 2021 - Mar 2021
2019 pullback2019
-8.37%Sep 2019
1mo 13d1mo 11d
2mo 24dAug 2019 - Nov 2019

Drawdown Indicators


FBIOPBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-73.54%

-56.78%

-16.76%

Max Drawdown (1Y)

Largest decline over 1 year

-31.05%

-9.10%

-21.95%

Max Drawdown (3Y)

Largest decline over 3 years

-70.75%

-18.90%

-51.85%

Max Drawdown (5Y)

Largest decline over 5 years

-73.54%

-25.43%

-48.11%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

0.00%

-0.74%

+0.74%

Average Drawdown

Average peak-to-trough decline

-22.25%

-10.72%

-11.53%

Ulcer Index

Depth and duration of drawdowns from previous peaks

15.40%

1.97%

+13.43%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Fortress Biotech, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Fortress Biotech, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for FBIOP relative to other companies in the Biotechnology industry. Currently, FBIOP has a P/S ratio of 37.4. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for FBIOP in comparison with other companies in the Biotechnology industry. Currently, FBIOP has a P/B value of 116.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with FBIOP

Add Fortress Biotech, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with FBIOP